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BACKGROUND: To assess the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation for unresectable stage III
non-small-cell lung cancer (NSCLC).
METHODS: Eligible patients were 20–74 years old and had histologically or cytologically confirmed NSCLC, a performance status of
0–1, and no prior chemotherapy. Patients were treated with cisplatin (60mgm
 2 on day 1) and S-1 (orally at 40mgm
 2 per dose,
b.i.d., on days 1–14), with the treatment repeated every 4 weeks for four cycles. Beginning on day 2, a 60-Gy thoracic radiation dose
was delivered in 30 fractions.
RESULTS: Of 50 patients, 48 were eligible. Partial response was observed in 42 patients (87.5%; 95% CI: 79.1–96.9%). This regimen
was well tolerated. Common toxicities included grade 3/4 neutropenia (32%), grade 3/4 leukopenia (32%), grade 3/4 thrombo-
cytopenia (4%), grade 3 febrile neutropenia (6%), grade 3 oesophagitis (10%), and grade 3 pneumonitis (5%). Median progression-
free survival was 12.0 months and median overall survival was 33.1 months. The 1- and 2-year survival rates were 89.5 and 56%,
respectively.
CONCLUSIONS: This chemotherapy regimen with concomitant radiotherapy is a promising treatment for locally advanced NSCLC
because of its high response rates, good survival rates, and mild toxicities.
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Lung cancer remains the leading cause of cancer-related
deaths worldwide (Jemal et al, 2007). Approximately 30% of
non-small-cell lung cancer (NSCLC) patients present with locally
advanced lung cancer (van Meerbeeck, 2001). A number of
randomised clinical trials support the conclusion that combined-
modality approaches improve survival compared with radio-
therapy alone for locally advanced lung cancer (Le Chevalier
et al, 1991; Non-Small Cell Lung Cancer Collaborative Group,
1995). Depending on the strategy used, chemotherapy may
have a cytotoxic role by eradicating distant micrometastases,
may have a radiosensitising role by improving local control,
or it perhaps may have a role in both effects. Recently, two
randomised trials using cisplatin plus older agents from the
1980s compared sequential with concurrent chemoradiotherapy
and showed superior survival with the concurrent approach
(Furuse et al, 1999; Curran et al, 2003). However, distant
metastases remain the major site of failure and it is also likely
that more effective chemotherapy will be required for further
improvement in results.
During the last decade, several new agents, such as paclitaxel,
gemcitabine, vinorelbine, and docetaxel, have been proven to
be more effective in metastatic NSCLC than the old regimens
(Bunn and Kelly, 1998; Johnson, 1999; Hoffman et al, 2000).
Because of dose-limiting toxicities (Choy et al, 1998; Vokes et al,
2002; Gandara et al, 2003; Zatloukal et al, 2004; Fournel et al, 2005;
Bedano et al, 2006; Kiura et al, 2008), these new agents have been
tested using a reduced dose or split dose within the newer concurrent
chemoradiation regimens. As yet, however, these new strategies have
not been proven to be more effective than the older regimens.
S-1 is a new oral fluoropyrimidine agent designed to enhance
anticancer activity and to reduce gastrointestinal toxicity through
the combined use of an oral fluoropyrimidine agent (tegafur), a
dihydropyrimidine dehydrogenase inhibitor (5-chloro-2,4-dihydroxy-
pyridine), and an orotate phosphoribosyl transferase inhibitor
(potassium oxonate; Shirasaka et al, 2000). S-1 has been shown to
have one of the highest levels of response as a single agent for
metastatic NSCLC (Kawahara et al, 2001). Moreover, two phase II
trials of S-1 plus cisplatin for advanced NSCLC (stage IIIB without
any indications for radiotherapy or stage IV) showed a response rate
of 32.7–47% and a median survival time of 11–16 months. In
addition, it shows very few severe gastrointestinal or haematological
toxicities (Ichinose et al, 2004; Endo et al, 2006). Received 24 February 2009; revised 22 May 2009; accepted 1 June 2009
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www.bjcancer.comIf the same doses of S-1 plus cisplatin used for advanced NSCLC
could be concurrently used with thoracic radiotherapy (TRT), this
regimen would be expected to have several advantages over
previous regimens. First, the radiation-sensitising effect of 5-FU
is well known clinically and S-1 also has been shown to act as a
radiosensitiser in preclinical models (Fukushima et al, 1998;
Harada et al, 2004). Second, in order to achieve radiosensitisation,
prolonged exposure is desirable, and as such, oral administration
is the most appealing route of administration. In addition, phase I
studies have shown that the half-life of 5-FU after oral S-1
administration has been found to be markedly prolonged
compared with that of 5-FU after intravenous administration
(van Groeningen et al, 2000; Yamada et al, 2003). Therefore, we
conducted a phase II trial using S-1 and cisplatin chemotherapy
with concurrent TRT for locally advanced NSCLC.
PATIENTS AND METHODS
Patient selection
Patient eligibility requirements for enrollment in this study
included cytologically or histologically documented NSCLC and
measurable disease at a locally advanced stage IIIA or IIIB.
Patients with T1–T3 and N2 disease if medically inoperable, T4
with any node size and extent, and those with N3 disease with any
tumour involvement were eligible. Additional eligibility criteria
included patient’s age from 20 to 74 years, no prior treatment,
Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1, projected life expectancy of at least 3 months, a leukocyte
count of 4000–12000ml
 1, platelet count of X100000ml
 1,
haemoglobin level of X9g per 100ml, serum bilirubin level of
p1.5mg per 100ml, serum aspartate aminotransferase and alanine
aminotransferase levels of p100IUl
 1, alkaline phosphatase level
of twice the upper limit of normal or less, normal creatinine level,
and partial pressure of arterial oxygen X65torr in room air.
For staging, all patients underwent a computed tomography
(CT) scan of the thorax, including the upper abdomen, and either a
brain CT scan or brain magnetic resonance imaging. A radio-
isotopic bone scan or a positron emission tomography (PET) scan
was also performed in all of the patients. Mediastinoscopies
were not performed and lymph node metastases were clinically
diagnosed based on the results of a CT scan and/or PET scan.
Patients with significant pleural effusions or pericardial effusion
seen on a CT scan were not eligible. Patients who were pregnant or
who had concomitant serious diseases, a concomitant malignancy,
or symptomatic cerebral involvement were excluded from the
study. The institutional ethics committee of each of the partici-
pating institutions approved the protocol and all patients provided
written informed consent before starting the study.
Treatment plan
Before therapy was begun, a CT scan of the tumour in the chest
was performed in order to determine tumour volume. Treatment
in eligible patients began with the administration of two cycles of
concurrent chemoradiotherapy that consisted of an oral adminis-
tration of S-1 (40mgm
 2) twice daily for days 1–14 along with a
60-min intravenous infusion of cisplatin (60mgm
 2) on day 1 and
then at 4-week intervals. For the radiation treatment, a 60-Gy dose
was given in 30 fractions over a 6-week period. At 2 weeks after
the last radiation treatment, patients received two more cycles of
consolidation chemotherapy that consisted of the same doses and
schedule as for the concurrent chemoradiotherapy. The oral doses
of S-1 for each patient were assigned based on the body surface
area. The three doses administered were 40mg (body surface area
o1.25m
2), 50mg (1.25o body surface area o1.50m
2), and 60mg
(body surface area X1.50m
2). Supportive care, which included
adequate hydration and antiemetics, was provided. The use of
granulocyte colony-stimulating factor during radiotherapy was not
permitted.
If changes in the laboratory variables after the start of treatment
occurred so that a leukocyte count of 43000ml
 1 or a neutrophil
count of 41500ml
 1or any of the other entry eligibility criteria for
the study were not met, subsequent courses of treatment were
withheld until the noted abnormality had resolved. If there was no
resolution of the abnormality within 6 weeks, the patient stopped
the protocol treatment but was included in the study analysis.
The doses of S-1 were reduced in the event of any of the
following toxicities during the previous treatment cycle: grade 4
haematological toxicity, or grade 3 or more non-haematological
toxicity. For the subsequent courses, S-1 was reduced from 60, 50,
or 40mg twice daily to 50, 40, and 25mg twice daily, respectively.
Radiation therapy
Chest irradiation began concurrently on day 2 in all patients. Two
different radiation target volumes were planned: the initial large-
field target volume, which consisted of primary tumour and
mediastinal lymph nodes, and the boost target volume, which
consisted of the primary and involved nodes. Radiation therapy
was delivered to the large-field volume (40Gy) followed by a boost
volume (20Gy) with a dose of 2Gy daily for 5 days each week for
6 weeks by a linear accelerator generating at least 4MeV photons.
The target volume of the primary tumour included the complete
extent of the radiographically defined visible primary tumour and
lymph nodes with a minimum 1.0- to 2.0-cm margin around the
mass. Contralateral hilar lymph nodes were not included. The
objectives were to restrict the relative volume of the normal lung
treated with a dose of 420Gy (V20) to o30%, and the maximum
spinal cord dose was restricted to o50Gy.
Evaluation of response and toxicity
All eligible patients who received any portion of the treatment were
considered assessable for response and toxicity. Chest X-rays,
complete blood counts, and blood chemistry measurements were
done weekly. The response was assessed based on the CT scan
findings that initially had been used to define the extent of the
tumour. The response was evaluated in accordance with the
Response Evaluation Criteria in Solid Tumors (Therasse et al,
2000). The response was confirmed for at least 4 weeks (for a
complete or partial response) or 6 weeks (for stable disease) after
it was first documented.
Progression-free survival (PFS) was defined as the time from
registration until objective tumour progression or death. Patients
whose disease had not progressed at the time of study treatment
discontinuation continued to be assessed until progression was
documented. Overall survival (OS) was defined as the time from
registration to death from any cause. Progression-free survival and
OS were estimated by the Kaplan–Meier method. Adverse events
were graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, Version 3.0.
Follow-up studies included a post-treatment CT scan at 4–6
weeks from the completion of all chemotherapy. Subsequently,
follow-up was every 3 months for 3 years, then every 6 months
until disease progression.
Statistical analysis
The primary end point of the study was the response rate, which
determined the sample size. For the first stage, Simon’s minimax
two-stage phase II design (Simon, 1989) was used to allow early
termination if the preliminary results indicated minimal efficacy.
We chose a 90% response rate as the experimental target level
and a 70% response rate as the minimal target level with a- and
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responses were observed among the 25 total assessable patients,
the treatment was considered worthy of further consideration. For
the second stage, an additional 25 patients were enrolled in order
to achieve an overall maximum response rate of 90% with a
confidence interval (CI) of 15%
RESULTS
Patient characteristics
A total of 50 patients (43 men and 7 women) were enrolled in the
trial between August 2005 and April 2007.
A radioisotopic bone scan was performed in 12 patients, a PET
scan in 28 patients, and both were performed in 10 patients. In one
patient, the PET scan did not show a bone metastasis, but a
radioisotopic bone scan showed a vertebral bone metastasis before
treatment. In another patient, a PET scan did not show an adrenal
metastasis, but adrenal swelling was detected by an abdominal CT
scan before treatment. Thus, the two patients were not eligible for
the study.
Patient characteristics are summarised in Table 1. The median
age was 63 years. The ECOG performance status was 0 for 72% and
1 for 28% of patients. Histological examinations indicated the
presence of the following cancer cell types: adenocarcinoma, 60%;
squamous, 28%; and other types, 12%. In total, 22 (44%) patients
had stage IIIA disease; 26 (52%) patients had stage IIIB; and 2 (4%)
patients had stage IV.
Treatment delivery
There were 48 patients eligible and assessable for toxicity and
response. All but one of these patients (98%) completed the
concurrent treatment protocol that consisted of two cycles of
chemotherapy and radiotherapy with a dose of 60Gy. Because of
grade 3 oesophagitis, one patient was unable to complete the
scheduled concurrent chemoradiotherapy. In total, 43 (90%)
patients received at least one cycle of consolidation chemotherapy.
Consolidation chemotherapy was started on day 57 to day 81
(median, day 63), and 39 (81%) patients completed two cycles of
consolidation chemotherapy.
A total of four patients were unable to complete the two cycles
of consolidation chemotherapy because of toxicities (grade 3
pneumonitis, grade 5 cerebral haemorrhage, grade 3 fatigue, and
delayed recovery of bone marrow function). In accordance with
the study protocol, dose reductions were necessary in 8 out of 48
patients during concurrent treatment (17%) and in 14 out of 43
patients during consolidation chemotherapy (32%).
The projected dose intensities of cisplatin and S-1 were 15 and
280mgm
 2 per week, respectively. The actual dose intensity of
cisplatin was 11.2–16mgm
 2 per week (mean: 13.8; 92% of the
projected dose intensity), and the actual dose intensity of S-1 was
135–296mgm
 2 per week (mean, 243; 87% of the projected dose
intensity).
The radiation dose intensity was 6.5–10Gy per week (mean,
9.77; 97.7% of the projected dose intensity).
Response to treatment
We observed that 24 out of 25 patients had a partial response in the
first stage, and therefore an additional 25 patients were enrolled.
Of 48 patients, none had a complete response, whereas 42
patients had a partial response and 6 patients had stable disease.
No patients had progressive disease. The overall response rate was
87.5% (95% CI: 79.1–96.9).
Toxicity of treatment
Major grade 3 and 4 toxicities for the concurrent chemoradio-
therapy phase are summarised in Table 2. Concurrent chemo-
radiotherapy was generally well tolerated. Although 5 out of the 48
(10%) assessable patients had grade 3 oesophagitis, none showed
grade 4 radiation-associated oesophagitis. The most common
grade 3/4 haematological toxicities were neutropenia (which
included two patients with grade 3 febrile neutropenia) and
leukopenia (25%). Grade 3/4 anaemia and thrombocytopenia were
uncommon (two patients each, 4%) and no patients were observed
to have grade 3/4 pneumonitis. Other grade 3/4 toxicities were
anorexia (3 patients, 6%), fatigue (2 patients, 4%), diarrhoea (2
patients, 4%) and increases in serum alanine aminotransaminase
or aspartate aminotransferase levels (one patient, 2%).
Table 2 also summarises the major grade 3 and 4 toxicities
for the 43 patients who received consolidation chemotherapy.
The most common grade 3/4 toxicity was neutropenia (which
occurred in 4 (10%) patients, which included one patient with
grade 3 febrile neutropenia). Grade 3 pneumonitis was observed in
2 (5%) patients. After steroid therapy, both patients responded and
showed improvement.
One patient developed hemiparesis on day 34 of the first
consolidation chemotherapy treatment. A brain CT scan showed
multiple brain metastases with cerebral haemorrhage, and the
patient died on the following day. Although no thrombocytopenia
and/or neutropenia were observed, we could not exclude the
possibility of treatment-related death.
Survival
For the current analysis, the median follow-up time was 25.4
months (range, 12–37.6). Of 48 patients, 30 (62.5%) had
recurrence of the disease, and to date, 21 of these patients have
died. Figure 1 shows OS and PFS for the patients enrolled in the
study. The median PFS was 12.0 months and the median OS was
33.1 months. The 1- and 2-year survival rates were 89.5 and 56%,
respectively. No correlation was apparent between PFS or OS and
sex, age, histology, disease stage, or smoking status.
Table 1 Patient characteristics
Characteristics No. of patients
Total no. of patients 50
Age, years
Median 63
Range 35–74
Sex
Men 43
Women 7
Performance status
03 6
11 4
Histology
Adenocarcinoma 30
Squamous 14
Other 6
Stage
IIIA 22
T1-3N2M0 22
IIIB 26
T1-3N3M0 9
T4N0-1M0 6
T4N2M0 9
T4N3M0 2
IV 2
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squamous histology and those with non-squamous histology
(adenocarcinoma plus other types). There were no differences
noted in the survival curves between the squamous and non-
squamous histologies.
Among 30 reported sites of first failure, 15 (50%) were distant,
12 (40%) were loco-regional, and 3 (10%) were both loco-regional
and distant (Table 3). The brain and lung were the most common
sites for distant metastases (17% each).
DISCUSSION
This is the first phase II study to investigate the use of the new oral
fluoropyrimidine agent, S-1, in the curative-intent therapy setting
of stage III NSCLC. Our data indicate positive results with only
mild toxicities after treatment consisting of concomitant radio-
therapy in addition to S-1 plus cisplatin administered at the same
doses as those used for advanced metastatic NSCLC. The median
OS of 33.1 months, and the 1- and 2-year survival rates of 89.5 and
56% are very encouraging.
The advantages of using concomitant chemoradiotherapy have
been shown by both the West Japan Lung Cancer Group study
trial, which evaluated mitomycin, vinblastine, and cisplatin
regimens, and the similarly designed Radiation Therapy Oncology
Group trial, which evaluated cisplatin and vinblastine (Furuse
et al, 1999; Curran et al, 2003). The concurrent chemoradiotherapy
arm in the Japanese study resulted in a median OS of 16.5 months
with survival rates at 1 and 2 years of 64.1 and 34.6%, respectively
(Furuse et al, 1999).
Table 2 Major toxicities
Concurrent chemoradiotherapy (N¼48) Consolidation chemotherapy (N¼43)
Grade 3 Grade 4 Grade 3 Grade 4
Toxicity No. % No. % No. % No. %
Haematologic
Leukopenia 11 23 1 2 3 7 0
Neutropenia 11 23 0 3 7 1 2
Febrile neutropenia 2 4 0 1 2 0
Thrombocytopenia 1 2 1 2 0 0
Anaemia 2 4 0 2 5 1 2
Non-haematologic
Nausea 1 2 0 0 0
Anorexia 3 6 0 2 5 0
Fatigue 2 4 0 1 2 0
ALT, AST 1 2 0 0 0
Pneumonitis 0 0 0 2 5 0
Oesophagitis 5 10 0 0 0
Constipation 2 4 0 0 0
Diarrhoea 2 4 0 0 0 0
Cerebral haemorrhage 1 (Grade5) 2
ALT¼alanine aminotransaminase; AST¼aspartate aminotransferase; Concurrent¼S-1 plus cisplatin, and TRT (N¼48); Consolidation¼S-1 plus cisplatin (N¼43).
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Figure 1 Kaplan–Meier overall survival (OS) and progression-free
survival (PFS) curves in all patients. The median PFS was 12.0 months and
the median OS was 33.1 months.
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Figure 2 Kaplan–Meier overall survival (OS) and progression-free
survival (PFS) curves for patients with non-squamous histology (adeno-
carcinoma plus large cell), and patients with squamous histology.
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British Journal of Cancer (2009) 101(2), 225–231 & 2009 Cancer Research UKRecently, new agents, such as paclitaxel, vinorelbine, docetaxel,
and gemcitabine, have been evaluated in several studies that
administered the agents in combination with platinum when using
an induction and/or concurrent strategy. However, for many of
these newer agents, the dose-limiting toxicities require that lower
doses be given during the concurrent phase (Choy et al, 1998;
Vokes et al, 2002; Kiura et al, 2003; Belani et al, 2005; Fournel et al,
2005).
The median PFS and the median OS for these new concurrent
regimens were 8.4–16.3 and 14.8–23.4 months, respectively.
Overall survival rates at 1 and 2 years were 56.3–76 and
25–54%, respectively. These results are not satisfactory. Compared
with these studies, the results of our study are exceptionally
good.
The increased response rate and prolonged survival seen in
this study could explain the radiation-sensitising effect resulting
from prolonged exposure to S-1, because it was administered orally
on a daily basis. The European Organization for Research and
Treatment of Cancer reported a randomised trial that evaluated
radiation alone, radiation plus cisplatin at 30mgm
 2,w e e k l y ,o r
radiation plus cisplatin at 6mgm
 2, daily (Schaake-Koning et al,
1992). Results showed an improvement in the OS for radiation plus
daily cisplatin as against that for radiation alone. However, the
analysis of the patterns of failure indicated there was improvement
in regional control only. Therefore, prolonged exposure to S-1 may
enhance the radiation effect and contribute to improved local
control.
Alternatively, it could be argued that prolonged survival was due
to substantial second-line treatment, especially epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), because
the median PFS in this study was 12.0 months, which is not
exceptionally good compared with previous reports. There were 16
out of 30 relapsed patients receiving substantial second-line
treatment. Although we did not analyse EGFR mutational status
in this study, 7 out of 30 relapsed patients received EGFR-TKIs.
Only one patient responded to an EGFR-TKI, hence the use of
EGFR-TKIs cannot exclusively explain the prolonged survival, and
it is unclear why we observed so much difference between the
median PFS and OS.
Another advantage of using this regimen is that there are only
mild toxicities and very few treatment interruptions. Overall, 98%
of our study patients completed the concurrent chemoradio-
therapy, and 90% of the patients received at least one cycle of
consolidation chemotherapy, resulting in a total of 81% of patients
completing the planned treatment.
Oesophagitis is the principal toxicity, but only 5 (10%) patients
developed grade 3/4 oesophagitis. A possible reason for mild
oesophagitis is that potassium oxonate may inhibit the form-
ation of 5-FU nucleotides in the oesophagus, thereby reducing
the radiation-sensitising effect in oesophagus rather than in the
tumour.
In addition, we observed grade 2 and 3 pulmonary toxicity in
only three and two patients, respectively, and there was no grade 5
pulmonary toxicity seen. The reason for the low incidence of
severe radiation pneumonitis is unclear, and one possible
explanation may be that it was due to the administration of TRT
using three-dimensional treatment planning.
Recently, two reports on phase I studies of split-dose S-1
and cisplatin combined with concurrent radiotherapy were
published (Kaira et al, 2008; Chikamori et al, 2009). However,
this split-dose regimen using cisplatin and S-1 has not been
investigated for advanced NSCLC, and we do not know the
potential efficacy of this chemotherapy. In addition, we cannot
consider our chemoradiotherapy regimen as full-dose chemo-
radiotherapy, because the actual dose intensities of cisplatin and
S-1 in this study were less than the dose intensities of a previous
phase II study (70 and 65% for cisplatin and S-1, respectively,
compared with the doses in the study reported by Endo et al,
2006).
Differences in the toxicity profile of S-1 as a single agent
were observed between Japanese and Caucasians in previous
studies (van Groeningen et al, 2000; Hoff et al, 2003). Although
haematological toxicities predominated in Japan, diarrhoea
was the dose-limiting toxicity in Western countries. In our
study, only Japanese patients were enrolled; the toxicity profile
of this chemoradiotherapy regimen may be different in
Caucasians.
There are several other new agents of interest for stage III
NSCLC. In particular, pemetrexed, which is a potent inhibitor
of thymidylate synthase, seems promising (Taylor et al, 1992;
Schultz et al, 1999). A recent phase III study showed that
pemetrexed plus cisplatin yielded efficacy results in advanced
NSCLC comparable to those for gemcitabine plus cisplatin
(Scagliotti et al, 2008). In addition, pemetrexed plus cisplatin
has an excellent safety profile; a recent phase I study showed
that a full dose of pemetrexed plus cisplatin in conjunction
with full-dose concurrent TRT is well tolerated (Brade et al,
2008). In patients with squamous carcinoma, however, cisplatin
plus pemetrexed resulted in significantly worse survival than
cisplatin/gemcitabine (Scagliotti et al, 2008). Using pemetrexed
in the stage III setting is disadvantageous because stage III
NSCLC may include squamous carcinoma more frequently than
is seen in stage IV NSCLC. Although S-1 is also a potent inhi-
bitor of thymidylate synthase, we did not observe any
differences in either the response rate or survival between the
squamous and non-squamous groups. However, because of
the small number of patients in this study, we are unable to
draw any solid conclusions, and it will be necessary to conduct
a larger study to compare the efficacies for the different
histology types.
Although we observed a high response rate for this regimen,
analysis of the initial sites of failure indicated that local failure
still occurred in half of the patients with recurrences, and
thus our results highlight the need for further improvement in
local control. With regard to local control, currently an addi-
tional treatment of interest for stage III NSCLC is dose escalation
of TRT that uses three-dimensional treatment planning. In a
recent randomised phase II study by the Cancer and Leukemia
Group B, this new strategy resulted in a median survival of 24
months and a 1-year survival rate of 66.7% (Socinski et al, 2008).
Therefore, we are currently in the process of testing full-dose S-1
and cisplatin chemotherapy in conjunction with concurrent high-
dose TRT that uses three-dimensional conformal radiation
therapy.
In conclusion, the response rates and survival of the patients
enrolled in this trial are most encouraging and compare favourably
with the results from similar multimodality studies. A further
randomised trial will be necessary to fully evaluate the usefulness
of these current findings.
Table 3 Sites of initial failure
Patients
First site of failure No. %
Local 12 40
Local+distant 3 10
Distant 15 50
Brain 5 17
Lung 5 17
Liver 2 7
Bone 2 7
Adrenal 1 3
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